Powered by a proprietary optical imaging technique — spatial frequency domain imaging (SFDI) — Clarifi™ offers clinicians a fast, reliable, objective method of assessing tissue oxygen saturation and hemoglobin concentration and distribution in patients with compromised circulation. Oxygenation is a key biomarker to identify areas of compromised tissue.
By accurately quantifying tissue oxygen saturation and hemoglobin concentration and distribution, Clarifi™ provides an early warning system for complications due to compromised circulation, including diabetic foot ulcers.
Powered by an advanced imaging technology known as SFDI, Clarifi™ quantifies and displays 5 key biomarkers:*
Tissue oxygen saturation is a necessary, but insufficient indicator of tissue health. The ability of Clarifi™ to measure hemoglobin concentration and distribution in the papillary and reticular dermis reveals otherwise unavailable insight into the delivery of oxygen-carrying hemoglobin to the capillary network.
Equipped with this new information, Clarifi™ helps clinicians identify at-risk patients earlier, quantify the nature and level of their risk, and target care to prevent complications.
*This information is intended for general guidance only and should not be interpreted as specific medical, diagnostic, or therapeutic recommendations.
A study published by Weinkauf et al. (Oct. 2018) in the Journal of Vascular Surgery “aimed to evaluate the ability of spatial frequency domain imaging (SFDI) … to assess lower extremity blood supply” compared to other noninvasive vascular tests including ankle-brachial index (ABI), toe-brachial index (TBI) and pedal Doppler waveforms. The study included 47 subjects with and without diabetes.
The study concluded “SFDI is a feasible, rapid, and easy-to-use widefield measurement of perfusion in a clinical setting. This first-of-use study suggests that the technology has potential to evaluate lower extremity perfusion in people with and without diabetes.”
Clarifi™ is designed to help clinicians identify compromised circulation that indicates a patient may be at risk for an ulceration or infection. As a fully integrated system that is easy to operate, Clarifi™ supports consistency in practice, enable early detection and intervention, potential to improve outcomes, and help reduce costs across the continuum of care.
The Clarifi™ Imaging System is easy and affordable for clinicians to integrate into their practice and supported by reimbursement (CPT code 0061U). Clarifi™ is a powerful new point-of-care imaging system designed to help clinicians identify pre-ulcerative circulatory compromise.